High dose IL-2-activated murine natural killer (A-NK) cells accumulate glycogen and granules, lose cytotoxicity, and alter target cell interaction in vitro.
Activated natural killer (A-NK) cells, defined by immunophenotype and selected by adherence to the plastic, were cultured from murine splenocytes for up to 10 days with the addition of 1000 U/ml of recombinant human IL-2 at 48 h intervals. During culture days 2-4 with high DNA synthesis the initially non-granulated small cells established large granular lymphocyte (LGL) morphology and then differentiated further into giant hypergranulated cells with huge accumulations of glycogen. Timed EM observations indicated that specific dual-compartment (lytic) granules arose by a sequence of events starting with neo-synthesis of small progenitors with a dense core and a few membranous lamellae at one pole. Core and vesicular regions probably expanded independently to give the mature organization of the granule. Eventually, the vesicular region of granules contained large amounts of multi-lamellar material and probable debris, and the dense core could be multiplied. Intracellular proteoglycans, visualized with Cupromeronic Blue cytochemistry, were organized in a three-dimensional network within the dense cores. In contrast with earlier reports, and in spite of several-fold increased granularity, the in vitro cytotoxicity of the A-NK cells against YAC-1 and B16 cells decreased after the third day of culture. A-NK cells with glycogen accumulations caused focal clearing in melanoma monolayers whereas younger effectors adhered to the targets. It is concluded that high dose IL-2 stimulation causes more far-going progressive morphological and functional differentiations of the A-NK cells than has previously been observed with bearing for the use of these cells in experimental adoptive immunotherapy.
Unger
M L
ML
Institute of Anatomy and Cell Biology, University of Gothenburg, Sweden.
Hokland
M
M
Basse
P H
PH
Nannmark
U
U
Johansson
B R
BR
D000818:Animals; D002448:Cell Adhesion; D002450:Cell Communication / Q000187:drug effects / Q000276:immunology*; D002451:Cell Compartmentation; D002455:Cell Division / Q000276:immunology; D002467:Cell Nucleus / Q000648:ultrastructure; D003594:Cytoplasmic Granules / Q000276:immunology / Q000378:metabolism* / Q000648:ultrastructure; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004306:Dose-Response Relationship, Immunologic; D006003:Glycogen / Q000096:biosynthesis / Q000378:metabolism* / Q000648:ultrastructure; D006801:Humans; D016130:Immunophenotyping; D002479:Inclusion Bodies / Q000648:ultrastructure; D007376:Interleukin-2 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000378:metabolism* / Q000648:ultrastructure; D050356:Lipid Metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008223:Lymphoma; D008247:Lysosomes / Q000648:ultrastructure; D008297:Male; D008546:Melanoma, Experimental; D051379:Mice; D008810:Mice, Inbred C57BL; D011509:Proteoglycans / Q000378:metabolism; D013997:Time Factors; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D011509:Proteoglycans; D006003:Glycogen